Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
about
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myelomaQuantification of clonal circulating plasma cells in relapsed multiple myelomaImprovement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneTrisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese populationLate relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up studyEconomic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece.The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myelomaImpact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma.Implications of continued response after autologous stem cell transplantation for multiple myeloma.Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma.Conventional and molecular cytogenetic analyses in Turkish patients with multiple myeloma.Risk Stratification in Multiple Myeloma.Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Mechanisms of Resistance in Multiple Myeloma.Incidence and prognostic value of recurrent chromosomal abnormalities in elderly patients with multiple myeloma.SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation.Microfluidic enrichment of plasma cells improves treatment of multiple myeloma.Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens.
P2860
Q30424188-8EA927B8-B432-481F-AF52-E7FF68333AD7Q30571858-8D28DB66-10CC-4CF0-AC9F-77F26A9D2EB6Q34149903-65300D1F-DE00-461E-9670-A6F35F846582Q34416126-B53A8228-D70A-467C-B386-689123E429D6Q35244883-4E87C846-A4FB-4BDF-8A7F-D886FE504959Q35485758-1689A52D-D628-4A62-A109-D526B9435DA7Q35849219-D6E4C082-9AA2-4D82-837D-966787059896Q36473629-75DE1D46-4883-4894-BFC0-FBF6733D7B2BQ36524579-C787AAF9-EE78-4C08-BD79-244DDFD346C4Q36768997-BA09CBEF-8B43-44C8-A1DD-860CDE06DE17Q36813990-3CC628AC-1649-45F1-ACBD-62588E3F8DC7Q36973054-9137CC80-E25D-4CE8-BB4B-606751081823Q37151681-977E07C1-15F3-416A-BE90-9F735FDCF4CFQ37228026-9828AA01-3531-4CE0-9E68-A7671358B195Q37584754-6B6B2805-1B1B-49C7-A2F8-770F9BB24C8BQ37703123-75483AAE-B16F-4ECA-981B-FF6CBDB70DDBQ38736249-959386A7-4F51-43F3-AC2A-9DB43CAFED9DQ38947433-6B2825BA-0573-4310-9AC5-575DE2E69BA2Q39177792-DAE119E0-1F9B-4DF8-89FF-F633EB8E240EQ39185604-AA561356-8C7A-4E87-824F-7C2F65ABA8BBQ39303373-AE7E6D26-85F0-464C-8267-3505CD75688AQ40575818-56A96454-EA31-4393-BA61-A9E87EF825CEQ41198089-F05B564F-1A0C-4A9B-B58A-7715D66FDD1DQ42184785-C09861A2-F0F7-48A4-B3AA-54D7EAD7F9DFQ52594460-79C4CFB7-3386-4F1C-85F1-82CFEF4F0FCAQ53063097-E8F1678E-C4F6-49BF-8280-9A1F787728DF
P2860
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evidence for cytogenetic and f ...... a in the era of novel therapie
@ast
Evidence for cytogenetic and f ...... a in the era of novel therapie
@en
type
label
Evidence for cytogenetic and f ...... a in the era of novel therapie
@ast
Evidence for cytogenetic and f ...... a in the era of novel therapie
@en
prefLabel
Evidence for cytogenetic and f ...... a in the era of novel therapie
@ast
Evidence for cytogenetic and f ...... a in the era of novel therapie
@en
P2093
P2860
P50
P356
P1476
Evidence for cytogenetic and f ...... a in the era of novel therapie
@en
P2093
A Keith Stewart
David D Dingli
Francis Buadi
Martha Q Lacy
P Leif Bergsagel
Philip R Greipp
Prashant Kapoor
Robert A Kyle
Shaji Kumar
Shirshendu Sinha
P2860
P304
P356
10.4065/MCP.2009.0677
P407
P577
2010-06-01T00:00:00Z